Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex's Kidney Disorder Drug VX-147 Reduces Proteinuria in Phase 2 Study

12/01/2021 | 09:27am EST


© MT Newswires 2021
All news about VERTEX PHARMACEUTICALS
01/26VERTEX PHARMACEUTICALS : Q4 2021 Presentation
PU
01/26Vertex Pharmaceutical 4Q Profit Rose on Higher Sales of Trikafta
DJ
01/26VERTEX PHARMACEUTICALS : Reports Fourth Quarter 2021 and Full Year Financial Results - For..
PU
01/26Vertex Pharmaceuticals Q4 2021 Adjusted EPS, Revenue Jump; Company Sets 2022 Product Sa..
MT
01/26VERTEX : Q4 Earnings Snapshot
AQ
01/26Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q4 EPS $3.37, vs. Str..
MT
01/26Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $2.07B, vs..
MT
01/26Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
BU
01/26EARNINGS REACTION HISTORY : Vertex Pharmaceuticals, 54.5% Follow-Through Indicator, 2.8% S..
MT
01/26UBS Adjusts Vertex Pharmaceuticals Price Target to $256 From $238, Maintains Buy Rating
MT
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 7 502 M - -
Net income 2021 2 295 M - -
Net cash 2021 8 192 M - -
P/E ratio 2021 25,8x
Yield 2021 -
Capitalization 57 608 M 57 608 M -
EV / Sales 2021 6,59x
EV / Sales 2022 5,37x
Nbr of Employees 3 400
Free-Float 99,7%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 226,58 $
Average target price 268,78 $
Spread / Average Target 18,6%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS3.18%57 608
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812
BEIGENE, LTD.-17.13%23 067